Stock Track | Haemonetics Soars 8.75% Pre-Market on Strong Q2 Earnings, Beating Estimates

Stock Track

Nov 06, 2025

Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company specializing in blood and plasma supplies and services reported earnings that significantly surpassed analyst expectations.

Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. This represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business. However, excluding CSL, the company's organic revenue increased by an impressive 9.4% for the quarter.

The company's adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99. This marks a 13.39% increase from the $1.12 per share reported in the same quarter last year. Furthermore, Haemonetics raised its total company fiscal 2026 guidance, signaling confidence in its future performance. The strong results and positive outlook appear to be driving investor enthusiasm, as reflected in the significant pre-market stock movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115980631"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115980631\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115980631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115980631","market":"hk","top_or_hot":-1,"title":"Stock Track | Haemonetics Soars 8.75% Pre-Market on Strong Q2 Earnings, Beating Estimates","media":"Stock Track","content":"<p>Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company specializing in blood and plasma supplies and services reported earnings that significantly surpassed analyst expectations.</p>\n\n<p>Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. This represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business. However, excluding CSL, the company's organic revenue increased by an impressive 9.4% for the quarter.</p>\n\n<p>The company's adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99. This marks a 13.39% increase from the $1.12 per share reported in the same quarter last year. Furthermore, Haemonetics raised its total company fiscal 2026 guidance, signaling confidence in its future performance. The strong results and positive outlook appear to be driving investor enthusiasm, as reflected in the significant pre-market stock movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haemonetics Soars 8.75% Pre-Market on Strong Q2 Earnings, Beating Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haemonetics Soars 8.75% Pre-Market on Strong Q2 Earnings, Beating Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company specializing in blood and plasma supplies and services reported earnings that significantly surpassed analyst expectations.</p>\n\n<p>Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. This represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business. However, excluding CSL, the company's organic revenue increased by an impressive 9.4% for the quarter.</p>\n\n<p>The company's adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99. This marks a 13.39% increase from the $1.12 per share reported in the same quarter last year. Furthermore, Haemonetics raised its total company fiscal 2026 guidance, signaling confidence in its future performance. The strong results and positive outlook appear to be driving investor enthusiasm, as reflected in the significant pre-market stock movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HAE","symbol_name":"美国血液技术","start_time":0,"source_url":"","article_id":"1115980631","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115980631","pubTimestamp":1762430785,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HAE":"美国血液技术"},"translate_title":"个股追踪|Haemonetics盘前大涨8.75%Q2盈利强劲超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1},"content_text":"Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company specializing in blood and plasma supplies and services reported earnings that significantly surpassed analyst expectations.\nHaemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. This represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business. However, excluding CSL, the company's organic revenue increased by an impressive 9.4% for the quarter.\nThe company's adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99. This marks a 13.39% increase from the $1.12 per share reported in the same quarter last year. Furthermore, Haemonetics raised its total company fiscal 2026 guidance, signaling confidence in its future performance. The strong results and positive outlook appear to be driving investor enthusiasm, as reflected in the significant pre-market stock movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}